Effects of orlistat on body mass index and serum lipids in overweight and obese adolescents: a meta-analysis.

IF 1.3 4区 医学 Q4 ENDOCRINOLOGY & METABOLISM
Lingnan Zhang, Chang Meng, Fang Zhang, Xinwei Jia, Junmin Xie, Yeran Zhu, Xiaozhe Zhou, Peng Liu
{"title":"Effects of orlistat on body mass index and serum lipids in overweight and obese adolescents: a meta-analysis.","authors":"Lingnan Zhang, Chang Meng, Fang Zhang, Xinwei Jia, Junmin Xie, Yeran Zhu, Xiaozhe Zhou, Peng Liu","doi":"10.1515/jpem-2024-0429","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>We performed a meta-analysis to compare the effects of orlistat on body mass index and serum lipids in overweight and obese adolescents.</p><p><strong>Methods: </strong>The meta-analysis was conducted to identify randomized controlled trials (RCTs) published up to 1 August 2024. PubMed, Embase, and Cochrane Library databases were searched. The outcome measures body mass index (BMI) and serum lipids, such as total cholesterol (TC), total triglycerides (TG), low-density lipoprotein (LDL), and high-density lipoprotein (HDL). The review of publications was conducted in accordance with the guidelines set forth in the Cochrane Handbook and the Preferred Reporting Project for Systematic Review and Meta-Analysis (PRISMA).</p><p><strong>Results: </strong>This study has been registered with INPLASY (number INPLASY202480052). A total of 696 patients were included in five randomized controlled trials. The orlistat group reduced BMI compared to placebo in the short term (MD=-0.73, 95 % CI: -1.44 to -0.02, p=0.04, I<sup>2</sup>=73 %) but appeared to have little effect in the long term (MD=-1.72, 95%CI: -3.55 to 0.12, p=0.07, I<sup>2</sup>=84 %). The exciting thing is that orlistat can significantly improve blood lipid levels in children, TC (MD=-8.11, 95 % CI: -10.88 to -5.33, p<0.05, I<sup>2</sup>=0 %), TG (MD=-3.22, 95 % CI: -5.58 to -0.86, p<0.05, I<sup>2</sup>=0 %), LDL (MD=-6.06, 95 % CI: -8.75 to -3.37, p<0.05, I<sup>2</sup>=0 %), and HDL (MD=0.87, 95 % CI: 0.13-1.61, p<0.05, I<sup>2</sup>=31 %).</p><p><strong>Conclusions: </strong>Orlistat has been linked to alter lipid levels in obese or overweight children. However, the evidence regarding its efficacy in reducing BMI is inconclusive, with inconsistent findings across short and long-term studies. Further randomized controlled trials are necessary to ascertain its long-term impact on prognosis.</p>","PeriodicalId":50096,"journal":{"name":"Journal of Pediatric Endocrinology & Metabolism","volume":" ","pages":"95-101"},"PeriodicalIF":1.3000,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pediatric Endocrinology & Metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1515/jpem-2024-0429","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/25 0:00:00","PubModel":"Print","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: We performed a meta-analysis to compare the effects of orlistat on body mass index and serum lipids in overweight and obese adolescents.

Methods: The meta-analysis was conducted to identify randomized controlled trials (RCTs) published up to 1 August 2024. PubMed, Embase, and Cochrane Library databases were searched. The outcome measures body mass index (BMI) and serum lipids, such as total cholesterol (TC), total triglycerides (TG), low-density lipoprotein (LDL), and high-density lipoprotein (HDL). The review of publications was conducted in accordance with the guidelines set forth in the Cochrane Handbook and the Preferred Reporting Project for Systematic Review and Meta-Analysis (PRISMA).

Results: This study has been registered with INPLASY (number INPLASY202480052). A total of 696 patients were included in five randomized controlled trials. The orlistat group reduced BMI compared to placebo in the short term (MD=-0.73, 95 % CI: -1.44 to -0.02, p=0.04, I2=73 %) but appeared to have little effect in the long term (MD=-1.72, 95%CI: -3.55 to 0.12, p=0.07, I2=84 %). The exciting thing is that orlistat can significantly improve blood lipid levels in children, TC (MD=-8.11, 95 % CI: -10.88 to -5.33, p<0.05, I2=0 %), TG (MD=-3.22, 95 % CI: -5.58 to -0.86, p<0.05, I2=0 %), LDL (MD=-6.06, 95 % CI: -8.75 to -3.37, p<0.05, I2=0 %), and HDL (MD=0.87, 95 % CI: 0.13-1.61, p<0.05, I2=31 %).

Conclusions: Orlistat has been linked to alter lipid levels in obese or overweight children. However, the evidence regarding its efficacy in reducing BMI is inconclusive, with inconsistent findings across short and long-term studies. Further randomized controlled trials are necessary to ascertain its long-term impact on prognosis.

奥利司他对超重和肥胖青少年体重指数和血脂的影响:一项荟萃分析。
目的:我们进行了一项荟萃分析,比较奥利司他对超重和肥胖青少年体重指数和血脂的影响。方法:对截至2024年8月1日发表的随机对照试验(rct)进行荟萃分析。检索PubMed、Embase和Cochrane图书馆数据库。结果测量身体质量指数(BMI)和血脂,如总胆固醇(TC)、总甘油三酯(TG)、低密度脂蛋白(LDL)和高密度脂蛋白(HDL)。根据Cochrane手册和首选系统评价和荟萃分析报告项目(PRISMA)的指南对出版物进行综述。结果:本研究已在INPLASY注册(编号INPLASY202480052)。5项随机对照试验共纳入696例患者。与安慰剂相比,奥利司他组在短期内降低了BMI (MD=-0.73, 95 % CI: -1.44至-0.02,p=0.04, I2=73 %),但在长期内似乎没有什么影响(MD=-1.72, 95%CI: -3.55至0.12,p=0.07, I2=84 %)。令人兴奋的是,奥利司他可以显著改善儿童的血脂水平,TC (MD=-8.11, 95 % CI: -10.88至-5.33,P2=0 %),TG (MD=-3.22, 95 % CI: -5.58至-0.86,P2=0 %),LDL (MD=-6.06, 95 % CI: -8.75至-3.37,P2=0 %),HDL (MD=0.87, 95 % CI: 0.13-1.61, P2=31 %)。结论:奥利司他与肥胖或超重儿童血脂水平的改变有关。然而,关于其降低BMI的有效性的证据尚无定论,短期和长期研究的结果不一致。需要进一步的随机对照试验来确定其对预后的长期影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.70
自引率
7.10%
发文量
176
审稿时长
3-6 weeks
期刊介绍: The aim of the Journal of Pediatric Endocrinology and Metabolism (JPEM) is to diffuse speedily new medical information by publishing clinical investigations in pediatric endocrinology and basic research from all over the world. JPEM is the only international journal dedicated exclusively to endocrinology in the neonatal, pediatric and adolescent age groups. JPEM is a high-quality journal dedicated to pediatric endocrinology in its broadest sense, which is needed at this time of rapid expansion of the field of endocrinology. JPEM publishes Reviews, Original Research, Case Reports, Short Communications and Letters to the Editor (including comments on published papers),. JPEM publishes supplements of proceedings and abstracts of pediatric endocrinology and diabetes society meetings.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信